Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum
暂无分享,去创建一个
C. Rogier | B. Pradines | N. Bourgeois | D. Malvy | P. Parola | F. Simon | A. Pascual | F. Benoit‐Vical | D. Maubon | S. Picot | G. Menard | P. Delaunay | C. Oeuvray | D. Basset | B. Faugère | Eric Didillon | G. Ménard | Aurélie Pascual
[1] C. Rogier,et al. Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum , 2012, Malaria Journal.
[2] B. Pradines,et al. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia , 2011, Malaria Journal.
[3] R. Price,et al. Ex Vivo Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax , 2011, Antimicrobial Agents and Chemotherapy.
[4] E. Winzeler,et al. Piperaquine Resistance Is Associated with a Copy Number Variation on Chromosome 5 in Drug-Pressured Plasmodium falciparum Parasites , 2011, Antimicrobial Agents and Chemotherapy.
[5] S. Briolant,et al. Absence of association between pyronaridine in vitro responses and polymorphisms in genes involved in quinoline resistance in Plasmodium falciparum , 2010, Malaria Journal.
[6] Shui-sen Zhou,et al. Geographical, meteorological and vectorial factors related to malaria re-emergence in Huang-Huai River of central China , 2010, Malaria Journal.
[7] R. Price,et al. In Vitro Activity of Pyronaridine against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax , 2010, Antimicrobial Agents and Chemotherapy.
[8] P. Newton,et al. An Open-Label, Randomised Study of Dihydroartemisinin-Piperaquine Versus Artesunate-Mefloquine for Falciparum Malaria in Asia , 2010, PloS one.
[9] S. Briolant,et al. Absence of Association between Piperaquine In Vitro Responses and Polymorphisms in the pfcrt, pfmdr1, pfmrp, and pfnhe Genes in Plasmodium falciparum , 2010, Antimicrobial Agents and Chemotherapy.
[10] O. Gaye,et al. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial , 2010, The Lancet.
[11] Sue J Lee,et al. Dihydroartemisinin-piperaquine versus chloroquine to treat vivax malaria in Afghanistan: an open randomized, non-inferiority, trial , 2010, Malaria Journal.
[12] P. Siba,et al. In vitro sensitivity of Plasmodium falciparum to conventional and novel antimalarial drugs in Papua New Guinea , 2010, Tropical medicine & international health : TM & IH.
[13] P. Rosenthal,et al. In Vitro Sensitivities of Plasmodium falciparum to Different Antimalarial Drugs in Uganda , 2010, Antimicrobial Agents and Chemotherapy.
[14] David A. Fidock,et al. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria , 2009, Nature Reviews Microbiology.
[15] P. Rosenthal,et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] P. Rosenthal,et al. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. , 2009, The Journal of infectious diseases.
[17] A. Nzila,et al. In Vitro Activities of Piperaquine, Lumefantrine, and Dihydroartemisinin in Kenyan Plasmodium falciparum Isolates and Polymorphisms in pfcrt and pfmdr1 , 2009, Antimicrobial Agents and Chemotherapy.
[18] K. Silamut,et al. Artemisinin resistance in Plasmodium falciparum malaria. , 2009, The New England journal of medicine.
[19] B. Mordmüller,et al. In vitro activity of pyronaridine against Plasmodium falciparum and comparative evaluation of anti-malarial drug susceptibility assays , 2009, Malaria Journal.
[20] Stephane Proux,et al. Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment , 2009, PloS one.
[21] David H. Gracias,et al. Compactness Determines the Success of Cube and Octahedron Self-Assembly , 2009, PloS one.
[22] S. Krudsood,et al. Role of Known Molecular Markers of Resistance in the Antimalarial Potency of Piperaquine and Dihydroartemisinin In Vitro , 2009, Antimicrobial Agents and Chemotherapy.
[23] C. Wongsrichanalai,et al. Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia , 2009, Malaria Journal.
[24] M. Fukuda,et al. Evidence of artemisinin-resistant malaria in western Cambodia. , 2008, The New England journal of medicine.
[25] B. Cissé,et al. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. , 2008, The Journal of infectious diseases.
[26] Kwaku Poku Asante,et al. An Open Label, Randomised Trial of Artesunate+Amodiaquine, Artesunate+Chlorproguanil-Dapsone and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria , 2008, PloS one.
[27] P. Rosenthal,et al. Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treating Uncomplicated Malaria: A Randomized Trial to Guide Policy in Uganda , 2008, PloS one.
[28] S. Croft,et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. , 2008, Acta tropica.
[29] K. Stȩpniewska,et al. Population Pharmacokinetics of Piperaquine after Two Different Treatment Regimens with Dihydroartemisinin-Piperaquine in Patients with Plasmodium falciparum Malaria in Thailand , 2008, Antimicrobial Agents and Chemotherapy.
[30] P. Rosenthal,et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] O. Gaye,et al. Efficacy and safety of artesunate plus amodiaquine in routine use for the treatment of uncomplicated malaria in Casamance, southern Sénégal , 2007, Malaria Journal.
[32] U. d’Alessandro,et al. A Randomised Controlled Trial to Assess the Efficacy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Peru , 2007, PloS one.
[33] P. Siba,et al. Pharmacokinetics and Efficacy of Piperaquine and Chloroquine in Melanesian Children with Uncomplicated Malaria , 2007, Antimicrobial Agents and Chemotherapy.
[34] R. Price,et al. Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.
[35] H. Myint,et al. Efficacy and safety of dihydroartemisinin-piperaquine. , 2007, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[36] F. Nosten,et al. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border , 2007, Malaria Journal.
[37] P. Rosenthal,et al. Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial , 2007, PLoS clinical trials.
[38] R. Price,et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] D. Warhurst,et al. Effects of Piperaquine, Chloroquine, and Amodiaquine on Drug Uptake and of These in Combination with Dihydroartemisinin against Drug-Sensitive and -Resistant Plasmodium falciparum Strains , 2007, Antimicrobial Agents and Chemotherapy.
[40] J. Chollet,et al. In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. , 2007, Experimental parasitology.
[41] F. Nosten,et al. An open label randomized comparison of mefloquine–artesunate as separate tablets vs. a new co‐formulated combination for the treatment of uncomplicated multidrug‐resistant falciparum malaria in Thailand , 2006, Tropical medicine & international health : TM & IH.
[42] J. Hamzah,et al. In Vitro Interactions between Piperaquine, Dihydroartemisinin, and Other Conventional and Novel Antimalarial Drugs , 2006, Antimicrobial Agents and Chemotherapy.
[43] J. Bras,et al. Les résistances aux médicaments antipaludiques , 2006 .
[44] C. Rogier,et al. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of Plasmodium falciparum isolates. , 2006, The American journal of tropical medicine and hygiene.
[45] C. Rogier,et al. In vitro activity of iron-binding compounds against Senegalese isolates of Plasmodium falciparum. , 2006, The Journal of antimicrobial chemotherapy.
[46] C. Rogier,et al. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. , 2006, The American journal of tropical medicine and hygiene.
[47] N. Day,et al. Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.
[48] T. Davis,et al. Piperaquine , 2005, Drugs.
[49] Nicholas J White,et al. Antimalarial drug resistance. , 2004, The Journal of clinical investigation.
[50] P. Ringwald,et al. In Vitro Activities of Piperaquine and Other 4-Aminoquinolines against Clinical Isolates of Plasmodium falciparum in Cameroon , 2003, Antimicrobial Agents and Chemotherapy.
[51] K. Bojang,et al. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial , 2000, The Lancet.
[52] P. Ringwald,et al. In Vitro Activities of Pyronaridine, Alone and in Combination with Other Antimalarial Drugs, against Plasmodium falciparum , 1999, Antimicrobial Agents and Chemotherapy.
[53] J. Karbwang,et al. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients. , 1998, British journal of clinical pharmacology.
[54] B. Pradines,et al. In-vitro activity of pyronaridine and amodiaquine against African isolates (Senegal) of Plasmodium falciparum in comparison with standard antimalarial agents. , 1998, The Journal of antimicrobial chemotherapy.
[55] N. White,et al. Preventing antimalarial drug resistance through combinations. , 1998, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[56] S. Croft,et al. Activity of pyronaridine and mepacrine against twelve strains of Plasmodium falciparum in vitro. , 1996, The Journal of antimicrobial chemotherapy.
[57] D. Kyle,et al. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. , 1996, The American journal of tropical medicine and hygiene.
[58] J. Le bras,et al. In vitro activity of pyronaridine against African strains of Plasmodium falciparum. , 1992, Annals of tropical medicine and parasitology.
[59] C. Lambros,et al. Synchronization of Plasmodium falciparum erythrocytic stages in culture. , 1979, The Journal of parasitology.
[60] J. Peter,et al. Malaria Journal BioMed Central , 2008 .
[61] B. Pradines,et al. In vitro susceptibility of African isolates of Plasmodium falciparum from Gabon to pyronaridine. , 1999, The American journal of tropical medicine and hygiene.
[62] W. Milhous,et al. In vitro activity of pyronaridine against field isolates and reference clones of Plasmodium falciparum. , 1988, The American journal of tropical medicine and hygiene.